The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.

@article{Fu2011TheIP,
  title={The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.},
  author={Tihui Fu and Qiuming He and P Sharma},
  journal={Cancer research},
  year={2011},
  volume={71 16},
  pages={5445-54}
}
The anti-CTL-associated antigen 4 (anti-CTLA-4) antibody ipilimumab is the first agent to show improved survival in a randomized phase III trial that enrolled patients with metastatic melanoma. Studies are ongoing to identify mechanisms that elicit clinical benefit in the setting of anti-CTLA-4 therapy. We previously reported that treated patients had an increase in the frequency of T cells expressing the inducible costimulator (ICOS) molecule, a T-cell-specific molecule that belongs to the… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

ICOS controls the pool size of effector-memory and regulatory T cells.

Journal of immunology • 2008
View 4 Excerpts
Highly Influenced

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 3 Excerpts

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.

Proceedings of the National Academy of Sciences of the United States of America • 2009
View 8 Excerpts

Similar Papers

Loading similar papers…